---
figid: PMC7924357__curroncol-28-00064-g001
figtitle: Angiogenesis pathways in malignancy and targeted therapies commonly used
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC7924357
filename: curroncol-28-00064-g001.jpg
figlink: pmc/articles/PMC7924357/figure/curroncol-28-00064-f001/
number: F1
caption: Angiogenesis pathways in malignancy and targeted therapies commonly used.
  Monoclonal antibodies including bevacizumab and ramucirumab and tyrosine kinase
  inhibitors including sunitinib, sorafenib, lenvatinib, pazopanib, axitinib, cediranib,
  and cabozantinib have been included (this list is not exhaustive). Receptors including
  VEGFR, c-kit, epidermal growth factor receptor (EGFR), fibroblast growth factor
  receptor (FGFR), and PDGFR are displayed here, but certain medications also target
  other pathways not displayed here such as AXL and RET. The VEGFR pathway intersects
  with multiple cell signaling pathways, including the PI3K/AKT/mTOR pathway. Created
  with Biorender.com.
papertitle: 'Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation:
  A Case Report and Review of the Literature.'
reftext: Lawrence Kasherman, et al. Curr Oncol. 2021 Feb;28(1):661-670.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9368138
figid_alias: PMC7924357__F1
figtype: Figure
redirect_from: /figures/PMC7924357__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7924357__curroncol-28-00064-g001.html
  '@type': Dataset
  description: Angiogenesis pathways in malignancy and targeted therapies commonly
    used. Monoclonal antibodies including bevacizumab and ramucirumab and tyrosine
    kinase inhibitors including sunitinib, sorafenib, lenvatinib, pazopanib, axitinib,
    cediranib, and cabozantinib have been included (this list is not exhaustive).
    Receptors including VEGFR, c-kit, epidermal growth factor receptor (EGFR), fibroblast
    growth factor receptor (FGFR), and PDGFR are displayed here, but certain medications
    also target other pathways not displayed here such as AXL and RET. The VEGFR pathway
    intersects with multiple cell signaling pathways, including the PI3K/AKT/mTOR
    pathway. Created with Biorender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - KITLG
  - EGF
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - PDGFB
  - BMP6
  - KIT
  - EGFR
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - PDGFRB
  - PDGFRA
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - H
  - Sunitinib
  - Pazopanib
  - Axitinib
  - Sorafenib
  - Cediranib
  - Lenvatinib
---
